- Report
- February 2024
- 120 Pages
Asia Pacific
From €4438EUR$4,950USD£3,792GBP
- Report
- February 2023
- 110 Pages
Global
From €3542EUR$3,950USD£3,026GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2501EUR$2,789USD£2,137GBP
- Report
- May 2024
- 137 Pages
Global
From €2689EUR$2,999USD£2,298GBP
€3586EUR$3,999USD£3,064GBP
- Report
- February 2024
- 95 Pages
Global
From €3500EUR$4,182USD£3,095GBP
- Report
- January 2024
- 111 Pages
Global
From €3500EUR$4,182USD£3,095GBP
The Myocardial Infarction Drug market is a subset of the Cardiovascular Drugs market, which includes drugs used to treat and prevent heart diseases. Myocardial Infarction Drugs are used to treat acute myocardial infarction (AMI), also known as a heart attack. These drugs are used to reduce the risk of death and complications from AMI, such as heart failure, arrhythmias, and stroke. Commonly used Myocardial Infarction Drugs include anticoagulants, antiplatelet agents, beta-blockers, and statins. These drugs are used to reduce the risk of blood clots, reduce inflammation, and lower cholesterol levels.
Some companies in the Myocardial Infarction Drug market include Pfizer, Merck, Sanofi, AstraZeneca, and Bristol-Myers Squibb. Show Less Read more
